Psychedelics could be a game-changer for millions dealing with depression, anxiety, addiction issues, PTSD, and even issues such as Parkinson’s disease.
With Parkinson’s, for example, about 10 million people struggle with it all over the world. Up to 60,000 people are diagnosed with it just in the U.S. every year. Worse, a Parkinson’s epidemic could be on the horizon, says Dr. Ray Dorsey, a neurologist at the University of Rochester Medical Center, as quoted by The Guardian. While there is no cure for Parkinson’s disease just yet, treatments such as L-dopa, or Levodopa can help control the symptoms, including stiffness, weakness, and rigidity. Unfortunately, even long-term exposure to L-dopa can cause issues, such as dyskinesia, which can include rapid, involuntary, and uncontrollable movements.
Luckily, there may be a solution for levodopa-induced dyskinesia in patients with Parkinson’s disease (LID-PD). In fact, PharmaTher just announced the successful completion of a Type B pre-Investigational New Drug meeting with the U.S. FDA regarding its proposed Phase 2 clinical study for ketamine in the treatment of LID-PD. Better, the US FDA already confirmed that a 505(b)(2) regulatory pathway is acceptable, which allows for the potential to accelerate the clinical development for drug approval.